ライフサイエンスコーパス: mucocutaneous candidiasis

1 entiation (STAT3, STAT1, CARD9) are prone to mucocutaneous candidiasis.

2 owever, they still had infections, including mucocutaneous candidiasis.

3 1 (STAT1) have been associated with chronic mucocutaneous candidiasis.

4 Four patients had recurrent mucocutaneous candidiasis.

5 t linkage assignment of a dominant locus for mucocutaneous candidiasis.

6 dism, autoimmune adrenocortical failure, and mucocutaneous candidiasis.

7 nic bacterial diseases and interleukin-17A/F mucocutaneous candidiasis.

8 hreatening autoimmune cytopenias and chronic mucocutaneous candidiasis.

9 s for immunodeficiency patients with chronic mucocutaneous candidiasis.

10 iseases, including invasive tuberculosis and mucocutaneous candidiasis.

11 d clinical manifestations, including chronic mucocutaneous candidiasis, AI, and asplenia, respectivel

12 Mucocutaneous candidiasis and dermatophyte infections oc

13 Most patients present with severe chronic mucocutaneous candidiasis and organ-specific autoimmunit

14 ator of transcription 1 (STAT1) with chronic mucocutaneous candidiasis and PML was reported previousl

15 ly, it will review key literature on chronic mucocutaneous candidiasis and psoriasis.

16 -17A/F and IL-6 are less common and underlie mucocutaneous candidiasis and staphylococcal diseases, r

17 linkage region on chromosome 2p for chronic mucocutaneous candidiasis and thyroid disease, previousl

18 matoceles, eczema, staphylococcal abscesses, mucocutaneous candidiasis, and abnormalities of bone and

19 ponses, improved TH17 differentiation, cured mucocutaneous candidiasis, and maintained remission of i

20 rized by multiple endocrine failure, chronic mucocutaneous candidiasis, and various ectodermal defect

21 in IL17F and IL17R in patients with chronic mucocutaneous candidiasis, as well as neutralizing autoa

22 mutations have been associated with chronic mucocutaneous candidiasis, but the role of CARD9 in inte

23 eficiency in mice or humans leads to chronic mucocutaneous candidiasis, but the specific downstream m

24 NCL-EPO-NPs also significantly abrogated mucocutaneous candidiasis by fluconazole-resistant strai

25 tor (AIRE) mutations, manifests with chronic mucocutaneous candidiasis (CMC) and multisystem autoimmu

26 Patients with chronic mucocutaneous candidiasis (CMC) are selectively unable t

27 Chronic mucocutaneous candidiasis (CMC) is characterized by recu

28 in humans have been associated with chronic mucocutaneous candidiasis (CMC), as well as with increas

29 have recently been shown to underlie chronic mucocutaneous candidiasis (CMC), while inborn errors of

30 such as disseminated candidiasis and chronic mucocutaneous candidiasis (CMC).

31 ukin-17F (IL-17F) or IL-17RA display chronic mucocutaneous candidiasis (CMC).

32 matophyte infections and suffer with chronic mucocutaneous candidiasis (CMC).

33 ial disease (hypomorphic alleles) to chronic mucocutaneous candidiasis (CMC; hypermorphic alleles).

34 rent bacterial infections, viral infections, mucocutaneous candidiasis, cutaneous warts, and skin abs

35 cells; meanwhile, some patients with chronic mucocutaneous candidiasis disease might also have viral

36 tor of transcription 1 (STAT1) cause chronic mucocutaneous candidiasis disease.

37 In patients with chronic mucocutaneous candidiasis, disease-associated polymorphi

38 rge family in which a combination of chronic mucocutaneous candidiasis (fungal infections of the skin

39 In patients with chronic mucocutaneous candidiasis, gain-of-function STAT1 mutati

40 lyendocrine syndrome type-1 (APS-1), chronic mucocutaneous candidiasis has been ascribed to neutraliz

41 autoimmune disorder characterized by chronic mucocutaneous candidiasis, hypoparathyroidism, and adren

42 pecies infection, Norwegian scabies, chronic mucocutaneous candidiasis, hypothyroidism, and esophagea

43 Mucocutaneous candidiasis in individuals with IL-17 immu

44 nti-IL-17F, or anti-IL-22 autoantibodies and mucocutaneous candidiasis in the setting of either APECE

45 ing the evolution of isolates from a chronic mucocutaneous candidiasis patient.

46 ciency (AI), hypoparathyroidism, and chronic mucocutaneous candidiasis plus autoantibodies neutralizi

47 About 25% of patients also display mucocutaneous candidiasis, probably owing to impaired in

48 ients with unusual susceptibility to chronic mucocutaneous candidiasis resulting from T(H)17 deficien

49 suffer from cold staphylococcal lesions and mucocutaneous candidiasis, severe allergy, and skeletal

50 nt, both subjects with mosaicism had chronic mucocutaneous candidiasis, suggesting that candidiasis i

51 17F.S65L) was identified that causes chronic mucocutaneous candidiasis, suggesting the existence of e

52 risingly, it is also associated with chronic mucocutaneous candidiasis, through as yet undetermined m

53 Data on patients affected by chronic mucocutaneous candidiasis underscore the preponderant ro

54 yeast infections and development of chronic mucocutaneous candidiasis were extensively studied.

55 -17A and interleukin-17F (IL-17A/F) underlie mucocutaneous candidiasis, whereas inborn errors of inte

56 utations, including recurrent infections and mucocutaneous candidiasis, which are suggestive of TH17

57 describe 2 patients presenting with chronic mucocutaneous candidiasis who harbor biallelic nonsense